These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 2795092

  • 1. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A, Savona S, Gafney E, Penichet KO, Lin BY, Levitt D, Ahmed T, Arlin ZA, Baskind P, Needleman D.
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT, Osgood B, Barna B, Boyett JM, Finke J, Medendorp SV, Murthy S, Novak C, Sergi J, Tubbs R.
    Cancer Res; 1989 Nov 15; 49(22):6432-6. PubMed ID: 2804986
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C.
    Eur J Cancer Clin Oncol; 1989 Nov 15; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 5. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Nat Immun; 1992 Oct 01; 11(3):133-43. PubMed ID: 1392401
    [Abstract] [Full Text] [Related]

  • 6. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 7. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 8. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH.
    J Clin Oncol; 1992 Feb 15; 10(2):275-81. PubMed ID: 1732429
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP, Ward D, Hemingway L, Hemstreet GP, Bradley E, Konrad M.
    Cancer Res; 1990 Oct 15; 50(20):6708-15. PubMed ID: 2208137
    [Abstract] [Full Text] [Related]

  • 10. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Oct 15; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 11. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B.
    J Biol Response Mod; 1990 Dec 15; 9(6):546-55. PubMed ID: 2074441
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
    Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH.
    J Natl Cancer Inst; 1990 Sep 05; 82(17):1397-402. PubMed ID: 2388289
    [Abstract] [Full Text] [Related]

  • 13. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK.
    N Engl J Med; 1987 Apr 09; 316(15):898-905. PubMed ID: 3493433
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF.
    J Clin Oncol; 2008 Apr 20; 26(12):2034-9. PubMed ID: 18347008
    [Abstract] [Full Text] [Related]

  • 15. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH.
    Eur J Cancer Clin Oncol; 1989 Apr 20; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [Abstract] [Full Text] [Related]

  • 16. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S.
    Clin Cancer Res; 1997 Apr 20; 3(4):565-72. PubMed ID: 9815721
    [Abstract] [Full Text] [Related]

  • 17. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW.
    Cancer J Sci Am; 2000 Feb 20; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [Abstract] [Full Text] [Related]

  • 18. The role of interleukin-2 in the biotherapy of cancer.
    Parkinson DR.
    Oncol Nurs Forum; 1989 Feb 20; 16(6 Suppl):16-20. PubMed ID: 2687810
    [Abstract] [Full Text] [Related]

  • 19. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J, Kirchner H, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():38-43. PubMed ID: 8692118
    [Abstract] [Full Text] [Related]

  • 20. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
    Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H.
    Cytotherapy; 2008 Apr 12; 10(6):625-32. PubMed ID: 18836917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.